XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segments (Tables)
 9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Operations and Assets for Operating Segments and Geographic Information Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 For the three months ended September 30,For the nine months ended September 30,
(In thousands)2022202120222021
Revenue from services:
Pharmaceutical$— $— $— $— 
Diagnostics142,856 340,163 616,259 1,244,312 
Corporate— — — — 
$142,856 $340,163 $616,259 $1,244,312 
Revenue from products:
Pharmaceutical$32,388 $36,882 $104,938 $106,490 
Diagnostics— — — — 
Corporate— — — — 
$32,388 $36,882 $104,938 $106,490 
Revenue from transfer of intellectual property and other:
Pharmaceutical$4,500 $8,768 $97,659 $22,585 
Diagnostics— — — — 
Corporate— — — — 
$4,500 $8,768 $97,659 $22,585 
Operating income (loss):
Pharmaceutical$(28,298)$28,625 $9,020 $(4,251)
Diagnostics(49,454)19,658 (150,537)116,670 
Corporate(10,068)(10,457)(29,467)(30,585)
$(87,820)$37,826 $(170,984)$81,834 
Depreciation and amortization:
Pharmaceutical$17,840 $6,080 $50,882 $20,500 
Diagnostics10,155 12,883 31,313 39,025 
Corporate— — — — 
$27,995 $18,963 $82,195 $59,525 
Loss from investment in investees:
Pharmaceutical$(43)$(53)$(359)$(163)
Diagnostics— — — — 
Corporate— — — — 
$(43)$(53)$(359)$(163)
Revenues:
United States$149,841 $354,586 $634,754 $1,269,749 
Ireland6,680 5,445 104,318 24,663 
Chile14,347 16,486 46,490 49,294 
Spain4,564 5,721 17,370 17,077 
Israel251 307 3,663 3,543 
Mexico3,886 3,162 11,691 8,619 
Other174 106 570 442 
$179,744 $385,813 $818,856 $1,373,387 
(In thousands)September 30,
2022		December 31,
2021
Assets:
Pharmaceutical$1,297,347 $1,114,460 
Diagnostics697,118 1,238,583 
Corporate230,320 46,672 
$2,224,785 $2,399,715 
Goodwill:
Pharmaceutical$290,474 $237,576 
Diagnostics283,025 283,025 
$573,499 $520,601